PAcM-AN: poly (N-acryloylmorpholine)-conjugated antisense oligonucleotides.

Area of Science:

• Bioconjugation Chemistry
• Oligonucleotide Therapeutics
• Polymer Science

Background:

• Antisense oligonucleotides (ASOs) are promising therapeutic agents.
• Improving ASO stability and delivery remains a challenge.
• Polymer conjugation offers a strategy to enhance oligonucleotide properties.

Purpose of the Study:

• To synthesize and characterize a novel amphiphilic poly (N-acryloylmorpholine) (PAcM)-oligonucleotide conjugate.
• To evaluate the conjugate's biophysical properties, including melting temperature and nuclease stability.
• To assess the conjugate's ability to induce RNase H activity and its antisense efficacy against HIV-1.

Main Methods:

• Liquid-phase stepwise synthesis was employed to link PAcM to oligonucleotide chains.
• Melting properties were analyzed to assess duplex stability.
• Nuclease stability was evaluated by incubation with nucleases.
• RNase H activity was measured to determine the conjugate's ability to trigger RNA degradation.
• Antisense activity was tested against an HIV-1 target sequence.

Main Results:

• A novel amphiphilic, high-molecular weight PAcM-oligonucleotide conjugate was successfully synthesized.
• The conjugate exhibited enhanced nuclease stability compared to unmodified oligonucleotides.
• The PAcM conjugate effectively elicited RNase H activity.
• Antisense activity against an HIV-1 target was demonstrated.

Conclusions:

• The developed PAcM-oligonucleotide conjugate represents a promising platform for antisense drug development.
• The conjugate's improved stability and RNase H-inducing capacity are key advantages.
• This approach holds potential for enhanced therapeutic efficacy in treating viral infections like HIV-1.